<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95884">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059356</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048143</org_study_id>
    <nct_id>NCT02059356</nct_id>
  </id_info>
  <brief_title>Ammonia Levels and Cognitive Decline in the Elderly</brief_title>
  <official_title>Prevalence of High Ammonia Levels in the Elderly With Cognitive Decline. Does Treatment Help?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose and objective of this study is to determine the prevalence of elevated ammonia
      levels in subjects with cognitive decline, and to observe if treating the cause of the
      elevated ammonia level improves mental status. This study does not include any imaging,
      treatment,or interventions, other than the blood draws. The blood draws will be taken to
      assess blood ammonia level and liver function. If the the ammonia level is not elevated, no
      further lab draws will occur. If the ammonia level is elevated, liver function is normal,
      and a cause for the high ammonia level is revealed with a plan for clinical treatment by the
      subjects' physician, then two more blood draws will occur; one prior to treatment, and one 3
      months after treatment. The main risk to subjects is related to the blood draw (i.e.
      momentary discomfort, bruising, infection, bleeding, clotting or fainting), and there is a
      potential loss of confidentiality. A paired student t test will be done with the two later
      blood to compare objective data.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in blood ammonia level</measure>
    <time_frame>Baseline, Pretreatment and 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in  mini-status examination</measure>
    <time_frame>Prior to treatment and 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dementia</condition>
  <condition>Cognitive Decline</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Non-cirrhotic patients with cognitive decline</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of assisted living center or the general public
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cognitive decline (suspected or documented)

          -  able to get blood drawn

        Exclusion Criteria:

          -  liver disease/cirrhosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gemini Janas, BS RT(R)(CV)</last_name>
    <phone>919-684-7277</phone>
    <email>gemini.janas@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemini Janas</last_name>
      <phone>919-684-7277</phone>
      <email>gemini.janas@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Suhocki, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's</keyword>
  <keyword>Alzheimers</keyword>
  <keyword>Cognitive decline</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Memory loss</keyword>
  <keyword>Memory disorder</keyword>
  <keyword>Forgetfulness</keyword>
  <keyword>Confusion</keyword>
  <keyword>Senile</keyword>
  <keyword>Demented</keyword>
  <keyword>Portal systemic shunting</keyword>
  <keyword>High ammonia level</keyword>
  <keyword>Elevated ammonia level</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
